Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

Chad A. Hamilton*, G. Larry Maxwell, Mildred R. Chernofsky, Sarah A. Bernstein, John H. Farley, G. Scott Rose

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

Background: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.

Original languageEnglish
Pages (from-to)530-532
Number of pages3
JournalGynecologic Oncology
Volume111
Issue number3
DOIs
StatePublished - Dec 2008
Externally publishedYes

Keywords

  • Ascites
  • Bevacizumab
  • Intraperitoneal
  • Ovarian cancer
  • Palliation

Fingerprint

Dive into the research topics of 'Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer'. Together they form a unique fingerprint.

Cite this